Lipoprotein-associated Phospholipase A2(Lp-PLA2) Determination Kit (ELISA)

2017-08-24

　　Generic name: Lipoprotein phospholipase A2 (Lp-PLA2) assay kit (ELISA)

　　English name: Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Determination Kit (ELISA)

　　[Medical Device Manufacturing Enterprise License No.】 Beijing Drug Administration firearms production

　　[Medical Device Registration Certificate No.] Beijing Food and Drug Administration Apparatus (Approved) 2015

 

▲ Product name

　　Generic name: Lipoprotein phospholipase A2 (Lp-PLA2) assay kit (ELISA)

　　English name: Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Determination Kit (ELISA)

　　[Medical Device Manufacturing Enterprise License No.】 Beijing Drug Administration firearms production Xu 20,040,085 No.

　　[Medical Device Registration Certificate No.] Beijing Food and Drug Administration Apparatus (Approved) No. 2015 2400412

 

▲ Packing

　　96 / box 48 servings / box 24 servings / box

 

▲ storage conditions and period

　　Storage conditions 2 ~ 8 ℃, preventing freezing, valid for 12 months.

　　After opening the package, please kit as soon as possible one-time run, each reagent components can not be reused.

 

▲ intended use

　　This kit for the quantitative detection of human plasma lipoprotein phospholipase A2 (Lp-PLA2) concentration, suitable for screening and diagnosis of coronary heart disease and stroke, and only for in vitro testing.

 

▲ Applicable models

　　This kit needs to be detected using a microplate reader, microplate reader detection wavelength of 450nm.

 

▲ Products

　　Lp-PLA2 belong phospholipase A2 superfamily, it is a serine lipase by a 441 amino acid residues, the relative molecular weight of 45kD. Lp-PLA2 in the blood is mainly composed of mature macrophages and lymphocytes synthesis and secretion in atherosclerosis sites abound, and can be adjusted inflammatory mediators involved in the formation of plaque, process and final rupture process.

　　Lp-PLA2 is a cerebrovascular disease associated with inflammatory markers, with the promotion of atherosclerosis (AS) effect, can increase the risk of ischemic stroke. Studies have shown that Lp-PLA2 in the middle-aged group content, causing greater risk of ischemic stroke. Lp-PLA2 is an independent predictor of cardiovascular disease, and cardiovascular disease linear correlation. In the detection of human circulating concentrations of LP-PLA2, could predict the future as a new, independent testing indicators of coronary heart disease, ischemic stroke and other cardiovascular and cerebrovascular diseases, clinical testing is very important.